For immediate release
June 20, 2016
Pillar5 Pharma Doubles Aseptic Capacity and Business With $11 Million Dollar Sterile Ophthalmic Investment
ARNPRIOR, ONTARIO - Pillar5 announces plans to double its sterile capacity by 2017, and is forecasting a 100% growth in sales over the next three to five years. A large contract signed this week with a leading US-based OTC company is helping to further this local company’s goals. The benefits to the company and local economy are numerous, including an increase in staff, which is clearly positive for the city and region, according to Dwight Gorham, Chief Executive Officer and President of Pillar5.
The plan to expand the Sterile Ophthalmic capacity; includes a doubling of the sterile fabrication area,a high-speed filler and a high-speed packaging line. It ideally positions Pillar5 to further pursue business in North American and European markets.
Since its inception, Pillar5’s willingness to invest in innovation has consistently resulted in significant increases in both sales and productivity. Strategically partnering with various sectors of government has provided Pillar5 with $4 million in funding in support of their ongoing, aggressive innovation plans.
Pillar5 continuously looks for ways to improve speed and responsiveness. They always aim to provide creative solutions to today’s challenges. This extreme commitment to customer service allows Pillar5 to partner with customers, helping navigate through FDA and Health Canada regulatory filings, to solve complex technical and transfer solutions, and to enable rapid access to target markets. “Anyone who requires a rapid product launch, transfer, or solutions to complex technical challenges, can depend on Pillar5 to offer lightning-speed solutions, exceeding all expectations.” states Jamie Moore, Chief Operating Officer.
Pillar5 was founded in 2009 by current CFO and VP of Business Development, Kevin Rampton, who assembled a group of successful investors and experienced executives to purchase the former award-winning Pfizer facility in Arnprior. Their focus was to rapidly turn the once proud Pfizer facility into an extremely competitive independent Contract Manufacturing Organization (CMO). They have quickly become a success story locally and within the industry.
All inquiries should be forwarded to Kevin Rampton at 613-623-1243.
— END PRESS RELEASE —